zurück

Dapagliflozin (new indication: chronic heart failure with left ventricular ejection fraction (LVEF) > 40 %)

 

Subject:

  • Active Substance: Dapagliflozin
  • Name: Forxiga®
  • Therapeutic area: Heart failure
  • Pharmaceutical company: AstraZeneca GmbH

 

Time table:

  • Start: 01.03.2023
  • Publication of assessment: 01.06.2023
  • End of public hearing: 22.06.2023
  • Final decision by G-BA: mddle of August 2023

 

Comparative therapy:

  • An optimized standard of care for the treatment of symptomatic chronic heart failure with preserved ejection fraction or modestly reduced ejection fraction and underlying conditions, such as hypertension, arrhythmias, coronary artery disease, diabetes mellitus, chronic kidney disease, dyslipoproteinemia, and associated symptoms.